VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
Share price
+$7.97 (+22.24%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
VERACYTE, INC. grew revenue 17.3% to $561.90M over the twelve months to Jun 30, 2026. Operating income rose 664.9% to $105.77M, moving the operating margin from 2.9% to 18.8%. Free cash flow was $165.99M, up 97.7% from a year earlier.
Revenue
$561.90M
+17.3% vs. a year earlier
Operating income
$105.77M
+664.9% vs. a year earlier
Free cash flow
$165.99M
+97.7% vs. a year earlier
EPS, diluted
$1.40
+324.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.59B
- P/E ratio
- 31.3
- Price to sales
- 6.40
- Price to book
- 2.59
- Dividend yield
- –
- Free cash flow yield
- 4.62%
Fundamentals
- Revenue
- $561.90M
- Net income
- $114.48M
- EPS, diluted
- $1.40
- Free cash flow
- $165.99M
- Book value per share
- $16.92
- Diluted shares
- 82M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$561.90M+17.3% YoY
Gross profit
$402.96M+23.2% YoY
Operating income
$105.77M+664.9% YoY
Net income
$114.48M+334.7% YoY
EPS, diluted
$1.40+324.2% YoY
Free cash flow
$165.99M+97.7% YoY
Reported periodTrailing twelve months